{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:22:15Z","timestamp":1791084135940,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bja.2019.08.010","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T18:00:48Z","timestamp":1571767248000},"page":"44-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review"],"prefix":"10.1016","volume":"124","author":[{"given":"Brian A.","family":"Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2019.08.010_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.biopsych.2005.11.016","article-title":"A\u00a0review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action","volume":"59","author":"Gillman","year":"2006","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib2","first-page":"419","article-title":"Extracting value from case reports: lessons from serotonin toxicity","volume":"61","author":"Gillman","year":"2006","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib3","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.10.12.1076","article-title":"Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor","volume":"10","author":"Oates","year":"1960","journal-title":"Neurology"},{"key":"10.1016\/j.bja.2019.08.010_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.bja.2019.08.010_bib6","series-title":"Adverse syndromes and psychiatric drugs","first-page":"37","article-title":"Serotonin syndrome","author":"Gillman","year":"2004"},{"key":"10.1016\/j.bja.2019.08.010_bib7","first-page":"103","article-title":"Serotonin syndrome (toxicity)","volume":"vol. 1","author":"Whyte","year":"2004"},{"key":"10.1016\/j.bja.2019.08.010_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.bja.2019.08.010_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.wnf.0000177642.89888.85","article-title":"The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment","volume":"28","author":"Isbister","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5694\/j.1326-5377.2007.tb01282.x","article-title":"Serotonin toxicity: a practical approach to diagnosis and treatment","volume":"187","author":"Isbister","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.bja.2019.08.010_bib11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0924-9338(03)00090-7","article-title":"Fatal interaction between tranylcypromine and imipramine","volume":"18","author":"Otte","year":"2003","journal-title":"Eur Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib12","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bja.2019.08.010_bib13","unstructured":"Gillman PK. Methylene blue and serotonin toxicity syndrome. Available from: https:\/\/psychotropical.info\/methylene-blue-serotonin-toxicity-syndrome\/(accessed 2 November 2018)."},{"key":"10.1016\/j.bja.2019.08.010_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.12659\/AJCR.897671","article-title":"Perioperative diagnosis and treatment of serotonin syndrome following administration of methylene blue","volume":"17","author":"Francescangeli","year":"2016","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.bja.2019.08.010_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/0003-4819-42-2-417","article-title":"Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis","volume":"42","author":"Mitchell","year":"1955","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bja.2019.08.010_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bmj.2.5104.1070","article-title":"Toxic effects of iproniazid in a patient with angina","volume":"2","author":"Papp","year":"1958","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bmj.2.5197.507","article-title":"Dangerous potentiation of pethidine by iproniazid, and its treatment","volume":"2","author":"Shee","year":"1960","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0140-6736(62)90080-6","article-title":"Reactions to other drugs in patients taking monoamine-oxidase inhibitors","volume":"2","author":"Clement","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2019.08.010_bib19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/bmj.2.5203.944-a","article-title":"Potentiation of pethidine","volume":"2","author":"Palmer","year":"1960","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/bmj.2.5318.1545-a","article-title":"Dangers of monoamine oxidase inhibitors","volume":"2","author":"Pells-Cocks","year":"1962","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/bmj.1.5275.408","article-title":"Pethidine and phenelzine","volume":"1","author":"Reid","year":"1962","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(62)90256-8","article-title":"Alarming reaction to pethidine in patients on phenelzine","volume":"280","author":"Taylor","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2019.08.010_bib23","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1136\/bmj.2.5321.1752-a","article-title":"Dangers of monoamine oxidase inhibitors","volume":"2","author":"Denton","year":"1962","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(63)91307-2","article-title":"Potentiation of amphetamine and pethidine by monoamineoxidase inhibitors","volume":"1","author":"Brownlee","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2019.08.010_bib25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/bmj.1.5332.750","article-title":"Dangers of monoamine oxidase inhibitors","volume":"1","author":"Spencer","year":"1963","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2019.08.010_bib26","first-page":"85","article-title":"Possible lethal reaction between nardil and dextromethorphan","volume":"103","author":"Rivers","year":"1970","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.bja.2019.08.010_bib27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(63)90265-4","article-title":"Reactions due to the combination of monoamineoxidase inhibitors with thymoleptics, pethidine or methylamphetamine","volume":"2","author":"Nymark","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2019.08.010_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1476-5381.1969.tb08003.x","article-title":"The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice","volume":"36","author":"Rogers","year":"1969","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0014-2999(71)90127-0","article-title":"Role of brain monoamines in the interaction between pethidine and tranylcypromine","volume":"14","author":"Rogers","year":"1971","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0079-6123(08)63971-0","article-title":"Blood platelet as a model for monoaminergic neurons","volume":"34","author":"Paasonen","year":"1971","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bja.2019.08.010_bib31","first-page":"7","article-title":"Blood platelets as models for neurons: uses and limitations","volume":"vol. 16","author":"Pletscher","year":"1980"},{"key":"10.1016\/j.bja.2019.08.010_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.1990.tb16873.x","article-title":"Serotonin uptake and serotonin uptake inhibition","volume":"600","author":"Fuller","year":"1990","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bja.2019.08.010_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.2042-7158.1969.tb08287.x","article-title":"Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines","volume":"21","author":"Carlsson","year":"1969","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1476-5381.1973.tb08208.x","article-title":"The effect of narcotic analgesics on the uptake of 5-hydroxytryptamine and (\u2013)-metaraminol by blood platelets","volume":"47","author":"Ahtee","year":"1973","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(25)29811-1","article-title":"Methadone inhibition of 3H-5-hydroxytryptamine uptake by synaptosomes","volume":"189","author":"Ciofalo","year":"1974","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/026988119801200201","article-title":"The serotonin transporter: a primary target for antidepressant drugs","volume":"12","author":"Schloss","year":"1998","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bcpt.1985.57.3.214","article-title":"5-HT-uptake inhibition potentiates antinociception induced by morphine, pethidine, methadone and ketobemidone in rats","volume":"57","author":"Larsen","year":"1985","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1016\/j.bja.2019.08.010_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1476-5381.1992.tb14226.x","article-title":"Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in\u00a0vitro","volume":"105","author":"Driessen","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3565(25)39454-1","article-title":"Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol","volume":"267","author":"Raffa","year":"1993","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib40","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.bjp.0701374","article-title":"Effect of acute and chronic tramadol on [3H]-5-HT uptake in rat cortical synaptosomes","volume":"122","author":"Giusti","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(99)00123-5","article-title":"Release studies with rat brain cortical synaptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blocker and not a 5-hydroxytryptamine releaser","volume":"370","author":"Gobbi","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","article-title":"(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel \u03bc-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","volume":"323","author":"Tzschentke","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib44","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/14656566.2012.696097","article-title":"Mechanistic and functional differentiation of tapentadol and tramadol","volume":"13","author":"Raffa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bja.2019.08.010_bib45","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/bja\/aei210","article-title":"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity","volume":"95","author":"Gillman","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bph.14105","article-title":"Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in\u00a0vitro: link to clinical reports of serotonin syndrome","volume":"175","author":"Rickli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00210-014-1056-3","article-title":"Effects of opioids on human serotonin transporters","volume":"388","author":"Barann","year":"2015","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2005.11.054","article-title":"Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis","volume":"531","author":"Barann","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0028-3908(91)90056-H","article-title":"Fentanyl and sufentanil inhibit agonist binding to 5-HT1A receptors in membranes from the rat brain","volume":"30","author":"Martin","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bja.2019.08.010_bib50","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00204-018-2244-6","article-title":"Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects","volume":"92","author":"Baldo","year":"2018","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib51","series-title":"List of antidepressants","year":"2018"},{"key":"10.1016\/j.bja.2019.08.010_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pharep.2017.07.011","article-title":"Drugs which influence serotonin transporter and serotonergic receptors: pharmacological and clinical properties in the treatment of depression","volume":"70","author":"Taciak","year":"2018","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bja.2019.08.010_bib53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jclinane.2012.05.002","article-title":"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil","volume":"25","author":"Davis","year":"2013","journal-title":"J\u00a0Clin Anesth"},{"key":"10.1016\/j.bja.2019.08.010_bib54","unstructured":"VigiBase. Available from: https:\/\/www.who-umc.org\/vigibase\/vigibase\/(accessed 29 December 2018)."},{"key":"10.1016\/j.bja.2019.08.010_bib55","series-title":"Drug safety communications: FDA warns about several safety issues with opioid pain medicines; requires label changes","author":"US Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.bja.2019.08.010_bib56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2710.2007.00813.x","article-title":"Serotonin syndrome caused by interaction between citalopram and fentanyl","volume":"32","author":"Ailawadhi","year":"2007","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jclinane.2007.06.024","article-title":"A\u00a0possible perianesthetic serotonin syndrome related to intrathecal fentanyl","volume":"20","author":"Ozkardesler","year":"2008","journal-title":"J\u00a0Clin Anesth"},{"key":"10.1016\/j.bja.2019.08.010_bib58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF03016672","article-title":"Serotonin toxicity caused by an interaction between fentanyl and paroxetine","volume":"55","author":"Rang","year":"2008","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jemermed.2008.01.003","article-title":"Serotonin syndrome precipitated by fentanyl during procedural sedation","volume":"38","author":"Kirschner","year":"2010","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.bja.2019.08.010_bib60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10620-009-0711-x","article-title":"Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy","volume":"55","author":"Alkhatib","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bja.2019.08.010_bib61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1213\/ANE.0b013e3181c76be9","article-title":"Serotonin syndrome in the perioperative period","volume":"110","author":"Altman","year":"2010","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2019.08.010_bib62","doi-asserted-by":"crossref","first-page":"D119","DOI":"10.1016\/j.encep.2009.03.010","article-title":"Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report","volume":"36","author":"Reich","year":"2010","journal-title":"Encephale"},{"key":"10.1016\/j.bja.2019.08.010_bib63","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/ALN.0b013e31823940c0","article-title":"Case scenario: opioid association with serotonin syndrome: implications to the practitioners","volume":"115","author":"Rastogi","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2019.08.010_bib64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jclinane.2011.04.017","article-title":"A\u00a0case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion","volume":"24","author":"Gollapudy","year":"2012","journal-title":"J\u00a0Clin Anesth"},{"key":"10.1016\/j.bja.2019.08.010_bib65","first-page":"156","article-title":"Serotonin syndrome: the potential for a severe reaction between common perioperative medications and selective serotonin reuptake inhibitors","volume":"5","author":"Adler","year":"2015","journal-title":"A\u00a0A Case Rep"},{"key":"10.1016\/j.bja.2019.08.010_bib66","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000382069","article-title":"Serotonin syndrome in a patient on trazodone and duloxetine who received fentanyl following a percutaneous liver biopsy","volume":"9","author":"Gaffney","year":"2015","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.bja.2019.08.010_bib67","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1002\/phar.1601","article-title":"Combined fentanyl and methadone induced serotonin syndrome is called into question","volume":"35","author":"Atkinson","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bja.2019.08.010_bib68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/phar.1528","article-title":"Serotonin syndrome caused by fentanyl and methadone in a burn injury","volume":"35","author":"Hillman","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bja.2019.08.010_bib69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.17085\/apm.2015.10.4.267","article-title":"A\u00a0case of postoperative serotonin syndrome following the administration of fentanyl, palonosetron, and meperidine\u2014a case report","volume":"10","author":"Lee","year":"2015","journal-title":"Anesth Pain Med"},{"key":"10.1016\/j.bja.2019.08.010_bib70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0253-7613.174575","article-title":"Serotonin syndrome presenting as pulmonary edema","volume":"48","author":"Shah","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.12659\/AJCR.909497","article-title":"Serotonin syndrome in the perioperative setting","volume":"19","author":"Smischney","year":"2018","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.bja.2019.08.010_bib72","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/BF03008376","article-title":"MAO inhibitors and coronary artery surgery: a patient death","volume":"39","author":"Noble","year":"1992","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/bja\/60.2.222","article-title":"Monoamine oxidase inhibitors and anaesthesia. A review","volume":"60","author":"Stack","year":"1988","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF03010890","article-title":"Monoamine oxidase inhibitors revisited","volume":"36","author":"Wells","year":"1989","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib75","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1213\/00000539-199403000-00030","article-title":"Cardiac surgery in a patient taking monoamine oxidase inhibitors: an adverse fentanyl reaction","volume":"78","author":"Insler","year":"1994","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2019.08.010_bib76","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1213\/00000539-198411000-00017","article-title":"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors","volume":"63","author":"Michaels","year":"1984","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2019.08.010_bib77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1213\/00000539-198506000-00006","article-title":"Monoamine oxidase inhibitors: should they be discontinued preoperatively?","volume":"64","author":"el-Ganzouri","year":"1985","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2019.08.010_bib78","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF03009749","article-title":"MAOI and cardiac surgery","volume":"40","author":"Baele","year":"1993","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib79","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/00007611-199708000-00014","article-title":"Monoamine oxidase inhibitors and cardiac anesthesia revisited","volume":"90","author":"Noorily","year":"1997","journal-title":"South Med J"},{"key":"10.1016\/j.bja.2019.08.010_bib80","first-page":"81","article-title":"Anesthesia for a patient on monoamine oxidase inhibitors","volume":"1","author":"Krishnan","year":"2016","journal-title":"Int J Adv Integ Med Sci"},{"key":"10.1016\/j.bja.2019.08.010_bib81","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/oxfordjournals.bja.a013453","article-title":"Safe use of remifentanil in a patient treated with the monoamine oxidase inhibitor phenelzine","volume":"84","author":"Ure","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF03020183","article-title":"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine","volume":"50","author":"Roy","year":"2003","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00000542-199304000-00003","article-title":"Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations","volume":"78","author":"Streisand","year":"1993","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2019.08.010_bib84","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/jnnp.69.2.281","article-title":"Acute adverse reaction to fentanyl in a 55 year old man","volume":"69","author":"Stuerenburg","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00000542-198709000-00012","article-title":"Ketanserin pretreatment reverses alfentanil-induced muscle rigidty","volume":"67","author":"Weinger","year":"1987","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2019.08.010_bib86","first-page":"E27","article-title":"Incidence of serotonin syndrome in patients treated with fentanyl on serotonergic agents","volume":"18","author":"Koury","year":"2015","journal-title":"Pain Physician"},{"key":"10.1016\/j.bja.2019.08.010_bib87","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12028-013-9914-2","article-title":"Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications","volume":"21","author":"Pedavally","year":"2014","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.bja.2019.08.010_bib88","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/sj.bjp.0705378","article-title":"Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors","volume":"139","author":"Tao","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib89","series-title":"Tramadol update review report: Expert committee on drug dependence (ECDD) 36th meeting agenda item 6.1, Geneva","author":"The WHO Expert Committee","year":"2014"},{"key":"10.1016\/j.bja.2019.08.010_bib90","first-page":"1029","article-title":"Influence of tramadol on neurotransmitter systems of the rat brain","volume":"46","author":"Frink","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bja.2019.08.010_bib91","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/bja\/79.3.352","article-title":"Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus","volume":"79","author":"Bamigbade","year":"1997","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib92","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0310057X0403200417","article-title":"Tramadol overdose and serotonin syndrome manifesting as acute right heart dysfunction","volume":"32","author":"Garrett","year":"2004","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.bja.2019.08.010_bib93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pediatrneurol.2010.08.005","article-title":"Serotonin syndrome induced by tramadol intoxication in an 8-month-old infant","volume":"44","author":"Marechal","year":"2011","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.bja.2019.08.010_bib94","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/201010581102000311","article-title":"Tramadol overdose: a case report","volume":"20","author":"Pothiawala","year":"2011","journal-title":"Proc Singapore Healthc"},{"key":"10.1016\/j.bja.2019.08.010_bib95","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/15563659709043367","article-title":"Prospective multicenter evaluation of tramadol exposure","volume":"35","author":"Spiller","year":"1997","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/15563650.2015.1036279","article-title":"Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely","volume":"53","author":"Ryan","year":"2015","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib97","first-page":"2086","article-title":"[Serotonin syndrome: review and case series from the Swiss pharmacovigilance system]","volume":"8","author":"Chassot","year":"2012","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.bja.2019.08.010_bib98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JCP.0000000000000344","article-title":"Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database","volume":"35","author":"Abadie","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib99","first-page":"395","article-title":"Tramadol, pharmacology, side effects, and serotonin syndrome: a review","volume":"18","author":"Beakley","year":"2015","journal-title":"Pain Physician"},{"key":"10.1016\/j.bja.2019.08.010_bib100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/pds.961","article-title":"Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants","volume":"14","author":"Shatin","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.bja.2019.08.010_bib101","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/2042098618760939","article-title":"Spontaneously reported adverse drug events related to tapentadol and oxycodone\/naloxone in Australia","volume":"9","author":"Abeyaratne","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.bja.2019.08.010_bib102","unstructured":"NUCYNTA ER (tapentadol). Highlights of prescribing information 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/200533s014lbl.pdf (accessed 29 October 2018)."},{"key":"10.1016\/j.bja.2019.08.010_bib103","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1310\/hpj4807-542","article-title":"ISMP adverse drug reactions. Serotonin syndrome with concomitant use of tapentadol and venlafaxine","volume":"48","author":"Mancano","year":"2013","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.bja.2019.08.010_bib104","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAF.0b013e3182887804","article-title":"Case report of a fatal intoxication by Nucynta","volume":"35","author":"Franco","year":"2014","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.bja.2019.08.010_bib105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1310\/hpj5104-320","article-title":"Probable tapentadol-associated serotonin syndrome after overdose","volume":"51","author":"Walczyk","year":"2016","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.bja.2019.08.010_bib106","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/15360288.2017.1416440","article-title":"Serotonin syndrome in tapentadol literature: systematic review of original research","volume":"31","author":"Gressler","year":"2017","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.bja.2019.08.010_bib107","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1310\/hpx5204-246","article-title":"Comment on tapentadol and serotonin syndrome","volume":"52","author":"Mullins","year":"2017","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.bja.2019.08.010_bib108","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1310\/hpx5204-248","article-title":"Comment on \u201cprobable tapentadol-associated serotonin syndrome after overdose\u201d","volume":"52","author":"Russo","year":"2017","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.bja.2019.08.010_bib109","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejphar.2017.04.013","article-title":"Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats","volume":"809","author":"Benade","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib110","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/0006-2952(73)90037-3","article-title":"Effect of p-chlorophenylalanine on the interaction between phenelzine and pethidine in conscious rabbits","volume":"22","author":"Mattila","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib111","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1553-2712.1999.tb01056.x","article-title":"Meperidine as a potential cause of serotonin syndrome in the emergency department","volume":"6","author":"Weiner","year":"1999","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.bja.2019.08.010_bib112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-3940(95)11364-3","article-title":"Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord","volume":"187","author":"Ebert","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bja.2019.08.010_bib113","doi-asserted-by":"crossref","first-page":"154","DOI":"10.23937\/2378-3656\/1410154","article-title":"A\u00a0dangerous triad: sertraline, mirtazapine and methadone","volume":"4","author":"Mart\u00edn-L\u00e1zaro","year":"2017","journal-title":"Clin Med Rev Case Rep"},{"key":"10.1016\/j.bja.2019.08.010_bib114","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/S0140-6736(00)03409-7","article-title":"Methadone, ciprofloxacin, and adverse drug reactions","volume":"356","author":"Herrlin","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bja.2019.08.010_bib115","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/j.1360-0443.2008.02390.x","article-title":"Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient","volume":"103","author":"Nair","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.bja.2019.08.010_bib116","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0033-3182(09)70868-0","article-title":"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine","volume":"50","author":"Lee","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bja.2019.08.010_bib117","first-page":"382","article-title":"Interaction between methadone and ciprofloxacin","volume":"63","author":"Samoy","year":"2010","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.bja.2019.08.010_bib118","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jamda.2005.04.012","article-title":"Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected?","volume":"6","author":"Gnanadesigan","year":"2005","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.bja.2019.08.010_bib119","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2165\/00002018-199207030-00004","article-title":"Dextromethorphan. An overview of safety issues","volume":"7","author":"Bem","year":"1992","journal-title":"Drug Saf"},{"key":"10.1016\/j.bja.2019.08.010_bib120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0166-4328(03)00193-1","article-title":"Involvement of the brain serotonergic system in the locomotor stimulant effects of chlorpheniramine in Wistar rats: implication of postsynaptic 5-HT1A receptors","volume":"148","author":"Karamanakos","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bja.2019.08.010_bib121","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/15563650802403534","article-title":"Comment on \u201cdextromethorphan-induced serotonin syndrome\u201d","volume":"46","author":"Karamanakos","year":"2008","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib122","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1002\/phar.1581","article-title":"Serotonin syndrome probably triggered by a morphine-phenelzine interaction","volume":"35","author":"Mateo-Carrasco","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bja.2019.08.010_bib123","doi-asserted-by":"crossref","DOI":"10.24150\/ajhm\/2018.010","article-title":"Hydromorphone precipitating serotonin syndrome","volume":"2","author":"Wang","year":"2018","journal-title":"Am J Hosp Med"},{"key":"10.1016\/j.bja.2019.08.010_bib124","first-page":"555663","article-title":"Serotonin syndrome in the post-anesthesia care unit after remifentanil infusion and ondansetron: a case report and literature review","volume":"5","author":"Ibarra","year":"2018","journal-title":"J\u00a0Anesth Intensive Care Med"},{"key":"10.1016\/j.bja.2019.08.010_bib125","first-page":"205","article-title":"Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features","volume":"2","author":"Marken","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib126","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.bja.2019.08.010_bib127","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.1999.00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline","volume":"48","author":"Gupta","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1006949816036","article-title":"Metabolism of tricyclic antidepressants","volume":"19","author":"Rudorfer","year":"1999","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.bja.2019.08.010_bib129","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jat\/bku034","article-title":"Variability in metabolism of imipramine and desipramine using urinary excretion data","volume":"38","author":"Ramey","year":"2014","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jat\/22.6.531","article-title":"Detection of doxepin and its major metabolite desmethyldoxepin in hair following drug therapy","volume":"22","author":"Negrusz","year":"1998","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib131","series-title":"Protriptyline. [Updated 2019 Jan 17]. StatPearls [Internet]","author":"Saef","year":"2019"},{"key":"10.1016\/j.bja.2019.08.010_bib132","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1984.42","article-title":"Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection","volume":"5","author":"Abernethy","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib133","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1192\/S000712500029747X","article-title":"Tyramine and irreversible monoamine oxidase inhibitors in clinical practice","volume":"6","author":"Cooper","year":"1989","journal-title":"Br J Psychiatr Suppl"},{"key":"10.1016\/j.bja.2019.08.010_bib134","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-199733020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of selegiline. An update","volume":"33","author":"Mahmood","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bja.2019.08.010_bib135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1527-3458.2003.tb00245.x","article-title":"Moclobemide: therapeutic use and clinical studies","volume":"9","author":"Bonnet","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.bja.2019.08.010_bib136","first-page":"406","article-title":"Antidepressant properties of trazodone","volume":"1","author":"Bryant","year":"1982","journal-title":"Clin Pharm"},{"key":"10.1016\/j.bja.2019.08.010_bib137","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/00000542-200306000-00033","article-title":"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use","volume":"98","author":"Tissot","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2019.08.010_bib138","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/bja\/aep167","article-title":"Meperidine-induced serotonin syndrome in a susceptible patient","volume":"103","author":"Guo","year":"2009","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib139","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1176\/ajp.150.5.837a","article-title":"Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome","volume":"150","author":"Coplan","year":"1993","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/bjaed\/mkw079","article-title":"Diagnosis and management of malignant hyperthermia","volume":"17","author":"Gupta","year":"2017","journal-title":"BJA Educ"},{"key":"10.1016\/j.bja.2019.08.010_bib141","first-page":"603","article-title":"Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors","volume":"88","author":"Isbister","year":"2002","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2019.08.010_bib142","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"Volpi-Abadie","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.bja.2019.08.010_bib143","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0310057X0503300205","article-title":"Serotonin syndrome and the anaesthetist","volume":"33","author":"Jones","year":"2005","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.bja.2019.08.010_bib144","first-page":"e1","article-title":"Cardiogenic shock due to Takotsubo cardiomyopathy associated with serotonin syndrome","volume":"7","author":"Sasaki","year":"2012","journal-title":"J\u00a0Cardiol Cases"},{"key":"10.1016\/j.bja.2019.08.010_bib145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s13181-011-0167-1","article-title":"Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose","volume":"7","author":"Levine","year":"2011","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.bja.2019.08.010_bib146","first-page":"568","article-title":"Reverse Takotsubo cardiomyopathy: after an episode of serotonin syndrome","volume":"38","author":"Mehta","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.bja.2019.08.010_bib147","doi-asserted-by":"crossref","first-page":"e15057","DOI":"10.1097\/MD.0000000000015057","article-title":"Takotsubo cardiomyopathy associated with serotonin syndrome in a patient with stroke: a case report","volume":"98","author":"Jang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bja.2019.08.010_bib148","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-2999(98)00195-2","article-title":"Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine","volume":"349","author":"Reimann","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib149","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1213\/00000539-198101000-00002","article-title":"Pharmacokinetics of high-dose meperidine in surgical patients","volume":"60","author":"Koska","year":"1981","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2019.08.010_bib150","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000542-199406000-00014","article-title":"Meperidine for patient-controlled analgesia after Cesarean section. Intravenous versus epidural administration","volume":"80","author":"Paech","year":"1994","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2019.08.010_bib151","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2011.12.008","article-title":"Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in\u00a0vivo microdialysis","volume":"507","author":"Tzschentke","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bja.2019.08.010_bib152","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2008.01.081","article-title":"Motor activity induces release of serotonin in the dorsal horn of the rat lumbar spinal cord","volume":"436","author":"Gerin","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bja.2019.08.010_bib153","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/syn.890180406","article-title":"Anesthetics block morphine-induced increases in serotonin release in rat CNS","volume":"18","author":"Tao","year":"1994","journal-title":"Synapse"},{"key":"10.1016\/j.bja.2019.08.010_bib154","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/jpet.102.038133","article-title":"GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system","volume":"303","author":"Tao","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-8993(97)00103-0","article-title":"Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in\u00a0vitro","volume":"755","author":"Jolas","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.bja.2019.08.010_bib156","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1017\/S146114570900011X","article-title":"Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice","volume":"12","author":"Fox","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib157","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00008571-200312000-00003","article-title":"Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bja.2019.08.010_bib158","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.bja.2019.08.010_bib159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"Zanger","year":"2004","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib160","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.bja.2019.08.010_bib161","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1213\/01.ane.0000189613.61910.32","article-title":"The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6","volume":"102","author":"Enggaard","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2019.08.010_bib162","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","article-title":"Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes","volume":"82","author":"Stamer","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bja.2019.08.010_bib163","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bja.2019.08.010_bib164","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002018-199207030-00005","article-title":"Adverse effects of systemic opioid analgesics","volume":"7","author":"Schug","year":"1992","journal-title":"Drug Saf"},{"key":"10.1016\/j.bja.2019.08.010_bib165","series-title":"Opioids in medicine","author":"Freye","year":"2008"},{"key":"10.1016\/j.bja.2019.08.010_bib166","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0310057X1204000204","article-title":"Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two","volume":"40","author":"Baldo","year":"2012","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.bja.2019.08.010_bib167","volume":"vols. 303\u20138","author":"Baldo","year":"2013"},{"key":"10.1016\/j.bja.2019.08.010_bib168","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jad.2008.03.009","article-title":"Trends in antidepressant use in the older population: results from the LASA-study over a period of 10 years","volume":"111","author":"Sonnenberg","year":"2008","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.bja.2019.08.010_bib169","series-title":"Essentials of pharmacology for anesthesia, pain medicine, and critical care","first-page":"797","article-title":"Serotonin syndrome","author":"Gayle","year":"2015"},{"key":"10.1016\/j.bja.2019.08.010_bib170","first-page":"871","article-title":"Antidepressants and the serotonin syndrome in general practice","volume":"49","author":"Mackay","year":"1999","journal-title":"Br J Gen Pract"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091219306324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091219306324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T18:54:08Z","timestamp":1757789648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091219306324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":170,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0007091219306324"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2019.08.010","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2019.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 British Journal of Anaesthesia. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}